{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:56:39Z","timestamp":1793861799121,"version":"4.6.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diagnosis-to-treatment interval (DTI) is an important prognostic factor in patients with newly diagnosed aggressive lymphomas, however the impact of DTI on outcomes in marginal zone lymphoma (MZL) is unknown. In this multicenter retrospective cohort study, we included adult patients with MZL\u00a0who received first-line immunochemotherapy within 120\u00a0days of diagnosis at 10 US medical centers. Patients who received treatment within 60\u00a0days from their diagnosis were classified into the short DTI group and those who received treatment beyond 60\u00a0days into long DTI group. The primary objective was progression-free survival (PFS), while secondary objectives included overall survival (OS) and cumulative incidence of histologic transformation (HT) between the two groups. Of the 870 patients with newly diagnosed MZL, 177 patients met the inclusion criteria and were included in this analysis. Among these 144 (81%) were in the short DTI group and 33 (19%) in the long DTI group. In the univariable analysis, presence of B symptoms was associated with short DTI and remained significantly associated with short DTI in the multivariable analysis (OR\u2009=\u200911.91, p\u2009=\u20090.017). Short DTI was not associated with a statistically different PFS or OS compared to long DTI in the univariable or in multivariable analysis. The cumulative incidence of HT was not significantly different between the two groups. This is the first study to-date to report on the association of DTI on outcomes in MZL patients. This lack of prognostic utility of DTI in newly diagnosed MZL, in contrast to aggressive B-cell lymphomas, may be intrinsically linked to the underlying disease\u00a0biology.<\/jats:p>","DOI":"10.1186\/s40164-025-00666-z","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:16:41Z","timestamp":1747210601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study"],"prefix":"10.1186","volume":"14","author":[{"given":"Narendranath","family":"Epperla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Shouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallawi","family":"Torka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Annunzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Anampa-Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen Ramakrishnan","family":"Geethakumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"16","key":"666_CR1","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","volume":"36","author":"MJ Maurer","year":"2018","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Link BK, et al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018;36(16):1603\u201310.","journal-title":"J Clin Oncol"},{"issue":"11","key":"666_CR2","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1182\/bloodadvances.2022009225","volume":"7","author":"N Epperla","year":"2023","unstructured":"Epperla N, Switchenko J, Bachanova V, et al. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv. 2023;7(11):2287\u201396.","journal-title":"Blood Adv"},{"issue":"12","key":"666_CR3","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","volume":"130","author":"C Thieblemont","year":"2017","unstructured":"Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. Blood. 2017;130(12):1409\u201317.","journal-title":"Blood"},{"issue":"12","key":"666_CR4","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","volume":"107","author":"L Arcaini","year":"2006","unstructured":"Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107(12):4643\u20139.","journal-title":"Blood"},{"issue":"17","key":"666_CR5","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1182\/bloodadvances.2023010133","volume":"7","author":"N Epperla","year":"2023","unstructured":"Epperla N, Zhao Q, Karmali R, et al. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study. Blood Adv. 2023;7(17):5038\u201346.","journal-title":"Blood Adv"},{"issue":"1","key":"666_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41408-024-01162-z","volume":"14","author":"NS Grover","year":"2024","unstructured":"Grover NS, Annunzio K, Watkins M, et al. Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study. Blood Cancer J. 2024;14(1):182.","journal-title":"Blood Cancer J"},{"issue":"9873","key":"666_CR7","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310.","journal-title":"Lancet"},{"issue":"19","key":"666_CR8","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944\u201352.","journal-title":"Blood"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00666-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00666-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00666-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:16:41Z","timestamp":1747210601000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00666-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00666-z","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board at OSU and was conducted in compliance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"PT: Honoraria\/consulting\/ad boards for Seagen, Pfizer, Abbvie, Bristol-Myers Squibb, TG Therapeutics, ADC Therapeutics, Genentech, GenMab and Lilly USA NSG: Research funding: Regeneron, Cabaletta, BMS, Affimed, Poseida. Honoraria\/consulting ad boards for ADC Therapeutics, Genentech, Novartis, BMS, Regeneron. RK: Advisory Board: BMS, Miltenyi, Abbvie, Genmab, Lilly USA, Genentech\/Roche; Grants\/Research Support: BMS. Speakers Bureau: AstraZeneca, BeiGene, Morphosys\/Incyte BC: Research funding: Genentech, Acerta, Millenium, Bristol-Myers Squibb, F Hoffman-La Roche; Advisory Board: Incyte, AstraZeneca SKB: Honoraria: Acrotech, Affimed, Daiichi Sankyo, Kyowa Kirin, Janssen, Seagen PRG: Consultancy services: Kite\/Gilead Pharma, Bristol Myers Squibb (BMS). Advisory board: Pharmacyclics LLC, ADC Therapeutics, Cellectar Biosciences, Ono Pharma, CRISPR therapeutics, IPSEN Biopharma, and Regeneron Pharmaceuticals. NLB: Research funding: ADC Therapeutics, Autolus, BMS, Celgene, Forty Seven, Genentech, Immune Design, Janssen, Merck, Millennium, Pharmacyclics, Affirmed Therapeutics, Dynavax, Gilead, MedImmune, Novartis; Consulting\/Ad board: Kite Pharma, Pfizer, ADC Therapeutics, Roche\/Genentech, Seattle Genetics, BTG, Acerta AJO: Genmab; Precision Bio; Adaptive Biotechnologies; Celldex; Acrotech Biopharma; Schrodinger; TG Therapeutics; Genentech. NE: Research funding (institutional): Beigene, Lilly, ADC Therapeutics, Ipsen and Incyte; Speakers Bureau for Beigene and Genetech, Ad boards for Ipsen and CRISPR Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}